The number of people receiving antiretroviral therapy (ART) in sub-Saharan Africa increased from 7.5 million in 2010 to 17 million in 2015 \[[@CIT0001]\], and expanded treatment access has led to substantial gains in life expectancy \[[@CIT0002]\]. The Joint United Nations Programme on HIV/AIDS (UNAIDS) aspires to further, fast-tracked improvements, with a target for 90% of patients knowing their human immunodeficiency virus (HIV) status, 90% being on ART, and 90% showing virological suppression by 2020 \[[@CIT0001]\]. The World Health Organization (WHO) has advocated a public health approach to HIV control in sub-Saharan Africa, centered on standardized regimens for first-line and second-line therapy and, since 2015, on prompt ART initiation regardless of CD4 cell counts \[[@CIT0003]\]. Recommended first-line regimens comprise 2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs), such as tenofovir disoproxil fumarate (TDF) and lamivudine (3TC), and a nonnucleoside reverse transcriptase inhibitor (NNRTI), principally efavirenz \[[@CIT0003]\]. Current recommended second-line regimens include 2 NRTIs such as zidovudine with 3TC, and a boosted protease inhibitor (PI), with lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir preferred. A recent network meta-analysis has highlighted the current lack of evidence for alternative second-line regimens other than LPV/r with raltegravir \[[@CIT0004]\]. As NRTIs are continued in second-line ART, NRTI resistance acquired during first-line ART might represent an important determinant of efficacy \[[@CIT0005], [@CIT0006]\].

In 2013, WHO recommended adoption of plasma viral load (VL) monitoring to enable early identification of treatment failure and appropriately guide treatment changes \[[@CIT0003]\]. The level of implementation varies across the region, and even in settings with access to routine VL testing, delays in switching to second-line ART are common \[[@CIT0007]\]. With further expansion in ART use, an increasing number of people in sub-Saharan Africa are at risk of treatment failure and drug resistance \[[@CIT0008]\].

To inform policy related to treatment selection, monitoring, patient management, and access to third-line therapy, systematically collated data on outcomes of second-line ART, impact of prior NRTI resistance, and risk of emergent protease resistance are needed. The aim of this study was to provide a comprehensive overview of data on effectiveness of second-line ART in sub-Saharan Africa and to present pooled estimates of virological and resistance outcomes.

METHODS {#s6}
=======

Search Strategy and Selection Criteria {#s7}
--------------------------------------

PubMed, Embase, the Cochrane Register of Controlled Trials, Scopus, and Web of Science were searched for articles published from 1 January 1996 to 28 July 2017 according to a predefined strategy ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). References cited in the selected articles and abstracts from the International AIDS Society Conference (2014--2016) and the Conference on Retroviruses and Opportunistic Infections (2014--2016) were also reviewed. We contacted the authors of 15 studies to clarify definitions, obtain additional data, and remove duplications.

### Types of Studies {#s8}

We included randomized controlled trials (RCTs) and observational studies that reported the outcomes of second-line ART in sub-Saharan Africa with VL measured at least annually. We excluded studies with \<20 participants, to avoid small-sample-size bias, and participants outside sub-Saharan Africa in international trials. We excluded studies without defined criteria for switching to second-line ART. For studies reporting the prevalence of drug resistance at second-line ART failure, we required that an unbiased selection method for resistance testing was applied, whereby either all patients meeting a defined VL threshold or a random selection were tested.

### Types of Participants {#s9}

Eligible studies investigated HIV type 1 (HIV-1)--infected participants aged \>10 years \[[@CIT0003]\] who received first-line ART with 2 NRTIs and 1 NNRTI for ≥6 months prior to switching to second-line ART, defined as ≥2 NRTIs with a ritonavir-boosted PI. Clinical, immunological, or virological criteria for switching to second-line ART were accepted, provided the criteria were clearly defined.

### Analyses {#s10}

The intention-to-treat (ITT) analysis described outcomes for all patients commencing second-line ART. Participants without virological data were categorized as lost to follow-up (no contact for ≥90 days since the last visit), died, transferred to another care provider, or missing data. The on-treatment analysis provided outcomes for participants who remained under follow-up with available VL results. For participants of observational studies who had commenced second-line ART but had not been in the study long enough to reach the virological analysis window, outcomes were imputed in proportion to the remaining participants in the cohort using a missing-at-random assumption. Data prior to imputation are presented in [Supplementary Tables 2--3](#sup1){ref-type="supplementary-material"}.

### Virological Outcomes {#s11}

The primary outcome was virological suppression, defined as plasma HIV-1 RNA \<400 copies/mL after 48 and 96 weeks of second-line ART, with a 24-week window period to allow for variations across studies (eg, measurements taken between weeks 36 and 60 were accepted for the 48-week outcome). The 400 copies/mL threshold was chosen to reflect the most commonly used definition of virological suppression in studies from the region. Outcomes were further categorized as low-level viremia (400--1000 copies/mL) and virological failure as per WHO definition (\>1000 copies/mL) \[[@CIT0003]\].

A secondary analysis explored how detection of NRTI resistance prior to starting second-line ART influenced virological outcomes at week 48. We included studies with available data using an on-treatment analysis. The overall activity of the second-line regimen was scored as either full or partial using the Stanford Resistance algorithm (version 8.2) \[[@CIT0009]\].

### Resistance {#s12}

The prevalence of major protease resistance mutations according to the Stanford Resistance algorithm (version 8.2) \[[@CIT0009]\] after 48 and 96 weeks was calculated as a proportion of the population that underwent resistance testing at failure.

Data Extraction {#s13}
---------------

Following the literature search and removal of duplicate citations, 2 reviewers (A. J. S., M. J. S.) independently screened the abstracts of retrieved records to include all potentially relevant articles, and then independently reviewed the full text of the remaining articles. Disputes about inclusion of articles were resolved through discussion, with recourse to a third reviewer (A. M. G.). A. J. S. and M. J. S. independently extracted data from the studies.

Quality Assessment {#s14}
------------------

We conducted this study according to recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CIT0010]\]. The quality of included articles was assessed using a modified version of a quality appraisal tool ([Supplementary Materials](#sup1){ref-type="supplementary-material"}). The review was registered with PROSPERO (CRD42016048985).

Statistical Analysis {#s15}
--------------------

Agreement between reviewers was assessed using Cohen κ statistic. Confidence intervals (CIs) were calculated using the Wilson method. Proportions were stabilized using the Freeman-Tukey arcsine square root transformation and a pooled proportion was calculated using the DerSimonian-Laird random effects model \[[@CIT0011]\]. To assess the effect of preexisting NRTI resistance on virological outcomes, we calculated the odds ratio (OR) of pooled rates of virological suppression at 48 weeks among patients receiving fully active regimens compared to those on partially active regimens, using a DerSimonian-Laird random effects model. We reported the *I*^2^ statistic, where *I*^2^ is interpreted as the proportion of variability in the treatment estimate attributable to between-study heterogeneity rather than sampling error. We assessed potential publication bias by visual inspection of funnel plots and by Egger test \[[@CIT0012]\].

To determine the effect on virological outcomes of study design (randomized vs observational), median CD4 cell count, year of study, and duration of first-line ART, we performed meta-regression analysis using a restricted maximum-likelihood estimator mixed effects model. Analyses were conducted in Stata version 14.2 software (StataCorp, College Station, Texas).

RESULTS {#s16}
=======

Data Selection and Quality Assessment: Virological Outcome Studies {#s17}
------------------------------------------------------------------

Following removal of duplicates, we screened 3525 abstracts and selected 206 full articles for review; the selection showed good agreement between reviewers (Cohen κ = 0.70 \[95% CI, .63--.76\]). Twenty articles describing 15 studies met the inclusion criteria ([Figure 1](#F1){ref-type="fig"}), comprising 5 RCTs \[[@CIT0006], [@CIT0013]\], 5 prospective observational studies \[[@CIT0019]\], and 5 retrospective observational studies \[[@CIT0026]\]. Six studies were reported from multinational cohorts \[[@CIT0013], [@CIT0019], [@CIT0023]\]. Data were available from 11 of 48 (23%) sub-Saharan African countries, with study locations in western, central, eastern, and southern Africa ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

![Flow diagram of search strategy. Abbreviations: ART, antiretroviral therapy; CROI, Conference on Retroviruses and Opportunistic Infections.](cix110801){#F1}

![Map of included studies.](cix110802){#F2}

###### 

Characteristics of Included Outcome Studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference, First Author                           Design   Year       Location                                                 No.    Age, y,\       Gender, % Female   Duration of First-line ART, mo, Median (IQR)   Frequency of Viral Load Monitoring   Second-line ART                                                
                                                                                                                                        Median (IQR)                                                                                                                                                                         
  ------------------------------------------------- -------- ---------- -------------------------------------------------------- ------ -------------- ------------------ ---------------------------------------------- ------------------------------------ ----------------- -------- ------------------ ---------------- ----------------
  La Rosa \[[@CIT0017]\]                            RCT      2012--13   Kenya, Malawi, South Africa, Tanzania, Zimbabwe          162    38 (33--43)    50                 48 (26--72)                                    6 mo                                 NA                VF       LPV                182 (160)^a^     4.5 (0.9)^a^

  Ciaffi \[[@CIT0015]\]                             RCT      2010--13   Cameroon, Senegal, Burkina Faso                          451    38 (32--46)    72                 49 (33--69)                                    3 mo                                 NA                VF       LPV 64%; DRV 34%   183 (87--290)    4.5 (4.0--51)

  Paton \[[@CIT0018]\]                              RCT      2010--14   Uganda, Kenya, Malawi, Zimbabwe, Zambia                  426    37 (31--43)    62                 48 (34--65)                                    None                                 NA                VF       LPV                72 (29--143)     4.8 (4.4--5.2)

  Boyd \[[@CIT0014]\];\                             RCT      2010--14   Nigeria, South Africa                                    100    38 (33--45)    65                 29 (19--50)                                    3 mo                                 NA                VF       LPV                199 (64--284)    4.2 (3.5--4.9)
  Amin \[[@CIT0013]\]                                                                                                                                                                                                                                                                                                        

  Gross \[[@CIT0016]\]                              RCT      2009--11   Botswana, South Africa, Uganda, Zambia, Zimbabwe         132    38 (34--45)    50                 34 (20- 55)                                    3 mo                                 NA                VF       LPV                183 (94--271)    4.3 (3.8--4.9)

  Osinusi-Adekanmbi \[[@CIT0022]\]                  POC      2008--11   Nigeria                                                  73     35 (30--41)    67                 24 (16--32)                                    6 mo                                 NA                VF       LPV                121              NA

  Shearer \[[@CIT0031]\]                            ROC      2004--12   South Africa                                             1150   38 (33--44)    59                 19 (13--31)                                    6 mo                                 NA                VF       LPV                203 (114--305)   4.2 (3.6--4.8)

  Schoffelen \[[@CIT0029]\]                         ROC      2004--10   South Africa                                             156    35 (29--41)    72                 19 (11--31)                                    6 mo                                 8                 VF       LPV                187 (93--299)    4.0 (3.4--4.5)

  Adetunji \[[@CIT0026]\]                           ROC      2006--09   Nigeria                                                  225    34 (29--40)    65                 16 (12--23)                                    6 mo                                 11                VF       LPV                139 (58--235)    4.6 (3.9--5.2)

  Wandeler \[[@CIT0024]\]                           POC      2006--12   South Africa                                             971    38 (32--45)    56                 27 (17--38)                                    6 mo                                 NA                C/I/VF   LPV                172 (95--267)    NA

  Boender \[[@CIT0019]\]; Sigaloff \[[@CIT0023]\]   POC      2007--11   Kenya, Nigeria, Uganda, South Africa, Zambia, Zimbabwe   243    38 (34--45)    50                 27 (15--44)                                    12 mo                                32                C/I/VF   LPV                126 (66--205)    4.2 (3.2--5.0)

  Murphy \[[@CIT0028]\]                             ROC      2006--10   South Africa                                             136    36 (31--43)    65                 13 (7--20)                                     6 mo                                 10                VF       LPV                153 (89--232)    4.5 (3.8--4.9)

  Johnston \[[@CIT0027]\]                           ROC      2003--08   South Africa                                             417    36 (31--44)    35                 23 (15--34)                                    6 mo                                 6                 VF       LPV                169 (97--235)    4.6 (4.1--5.1)

  Hosseinipour \[[@CIT0021]\]                       POC      2006--08   Malawi                                                   101    38 (32--46)    55                 35 (25--49)                                    3 mo                                 8                 VF       LPV                65 (22--173)     4.7 (4.1--5.2)

  Castelnuovo \[[@CIT0020]\]                        POC      2004--06   Uganda                                                   40     39 (36--43)    50                 22 (19--23)                                    6 mo                                 47                VF       LPV                108 (43--205)    4.8 (4.0--5.4)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ART, antiretroviral therapy; C, clinical failure; DRV, darunavir with ritonavir; I, immunological failure; IQR, interquartile range; LPV, lopinavir with ritonavir; NA, data not available; PI, protease inhibitor; PY, patient-years; POC, prospective observational cohort; RCT, randomized controlled trial; ROC, retrospective observational cohort; VF, virological failure.

^a^Mean (standard deviation).

Assessment of study quality is shown in [Supplementary Table 4](#sup1){ref-type="supplementary-material"}. The size of the initial first-line ART population, the rate of first-line ART failure, and the rate of switching to second-line ART were poorly described. The NRTIs used in first- and second-line regimens were inconsistently reported. The rate of adverse events and the contribution of tolerability to treatment discontinuation were not reported in most studies. In one study, criteria for starting second-line ART were at risk of performance bias as they included a requirement for regular attendance at clinic \[[@CIT0020]\]. Sensitivity analysis excluding this trial from the ITT and on-treatment analyses did not significantly alter pooled estimates. There was no evidence of publication bias on inspection of funnel plots and by Egger test of asymmetry at 48 or 96 weeks (*P* = .16 and *P* =.19, respectively; [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

Outcomes of Second-line ART {#s18}
---------------------------

The median duration of first-line ART prior to starting second-line ART varied from 13 to 49 months ([Table 1](#T1){ref-type="table"}). Estimates of the rate of switching from first-line to second-line ART were calculable for 8 studies and ranged from 6 to 47 per 1000 patient-years. All studies used twice-daily LPV/r; 1 RCT randomized one-third of participants to ritonavir-boosted darunavir (800 mg once daily) \[[@CIT0015]\]. By ITT, virological suppression rates were 69.3% (95% CI, 58.2%--79.3%) among 4558 participants from 14 studies at week 48, and 61.5% (95% CI, 47.2%--74.9%) among 2145 participants from 8 studies at week 96 ([Figure 3](#F3){ref-type="fig"} and [Supplementary Tables 2--3](#sup1){ref-type="supplementary-material"}). In the on-treatment analysis, suppression rates were 82.7% (95% CI, 76.9%--87.8%) among 3626 participants from 15 studies at week 48, and 84.8% (95% CI, 78.8%--89.9%) among 1090 participants from 8 studies at week 96 ([Figure 4](#F4){ref-type="fig"} and [Supplementary Table 5](#sup1){ref-type="supplementary-material"}). The rate of virological failure according to the WHO definition (\>1000 copies/mL) ranged between 2.5% and 26.6% of participants at 48 weeks and between 4.1% and 11.1% at 96 weeks, while low-level viremia occurred in 0--3.3% at 48 weeks and 0--5.0% at 96 weeks, respectively ([Supplementary Tables 2--3](#sup1){ref-type="supplementary-material"}).

![Forest plot of virological suppression at 48 weeks (*A*) and 96 weeks (*B*): intention--to-treat analysis, random effects model. Abbreviations: CI, confidence interval; VL \<400, viral load \<400 copies/mL.](cix110803){#F3}

![Forest plot of virological suppression at 48 weeks (*A*) and 96 weeks (*B*): on-treatment analysis, random effects model. Abbreviations: CI, confidence interval; VL \<400, viral load \<400 copies/mL.](cix110804){#F4}

Rates of virological suppression were significantly higher among participants of RCTs compared to observational cohorts at both week 48 (85.7% \[95% CI, 80.6%--90.2%\] vs 58.2% \[95% CI, 48.2%--68.0%\]; *P* \< .001) and week 96 (76.5% \[95% CI, 72.8%--80.4%\] vs 55.7 \[95% CI, 43.1%--67.8%\]; *P* \< .001). After exclusion of missing VL data, the difference between RCTs and observational cohorts persisted (*P* \< .0001 and *P* = .001 at 48 and 96 weeks, respectively), and estimates of virological suppression rates did not significantly change (*P* = .39 and *P* = .58 at 48 and 96 weeks, respectively). By meta-regression analysis, neither median CD4 cell count, nor median duration of first-line ART at the time of starting second-line, nor the year of study recruitment were significantly associated with virological suppression, after adjustment for study design (*P* = .37, *P* = .83, and *P* = .95, respectively, at week 48; *P* = .91, *P* = .74, and *P* = .28, respectively, at week 96).

Effect of Preexisting NRTI Resistance {#s19}
-------------------------------------

Resistance test results (by conventional sequencing) were available for 6 studies \[[@CIT0006], [@CIT0014], [@CIT0018], [@CIT0020], [@CIT0021], [@CIT0023], [@CIT0030]\]. The likelihood of virological suppression at week 48 was lower (OR, 0.31 \[95% CI, .14--.70\]; *P* = .020) among participants lacking evidence of NRTI resistance and therefore predicted to be receiving fully active second-line ART, relative to those with NRTI resistance receiving partially active second-line ART ([Figure 5](#F5){ref-type="fig"}). Preexisting NRTI resistance comprised predominantly the 3TC mutation M184V (67.0%--92.7% of participants) and thymidine analogue mutations (12.5%--74.3% of participants) ([Supplementary Table 6](#sup1){ref-type="supplementary-material"}).

![Forest plot: odds ratio for virological suppression at 48 weeks among participants with fully active compared to partially active second-line antiretroviral therapy (ART). Partially active ART is defined as low-level or greater resistance to any component of second-line ART (Stanford database version 8.2) \[[@CIT0009]\]. Abbreviations: CI, confidence interval; OR, odds ratio; VL\<400, viral load \<400 copies/mL.](cix110805){#F5}

Protease Resistance at Failure of Second-line ART {#s20}
-------------------------------------------------

Resistance test results (by conventional sequencing) were available from 649 participants from 13 studies, including 5 prospective \[[@CIT0014], [@CIT0015], [@CIT0018], [@CIT0023], [@CIT0030]\] and 8 cross-sectional studies \[[@CIT0032]\]. The threshold for resistance testing ranged from 400 to 5000 copies/mL. Duration of second-line ART at the time of sequencing ranged from 6 to 37 months. Major protease resistance mutations were present in a median of 17% (interquartile range, 0--25%; range, 0--66.7%) of patients who underwent resistance testing ([Table 2](#T2){ref-type="table"}). An association between the prevalence of protease resistance mutations and median duration of second-line ART was observed (0--11.8% at 6--12 months to 0--28.9% at 16--24 months, and 16.7%--66.7% at 27--37 months; *r*^2^ = 0.75, *P* \< .001). ([Figure 6](#F6){ref-type="fig"}).

###### 

Protease Inhibitor Resistance at Failure of Second-line Antiretroviral Therapy

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                               Study Design   Year       Location                                                 Total Population,\   Second-line ART Duration, mo, Median (IQR)   Viral Load Threshold for Sequencing, Copies/mL   Failure Population,\   Resistance Analysis Population, No. (%)   Protease Resistance,\              Protease Resistance,\           Major Protease Mutation (No.)
                                                                                                                             No.                                                                                                                No. (%)                                                          No. (% of At-Risk Population)^a^   No. (% of Those Sequenced)^b^   
  --------------------------------------- -------------- ---------- -------------------------------------------------------- -------------------- -------------------------------------------- ------------------------------------------------ ---------------------- ----------------------------------------- ---------------------------------- ------------------------------- -----------------------------------------------------------------------------------------
  Prospective studies                                                                                                                                                                                                                                                                                                                                                               

   Paton \[[@CIT0018]\]                   RCT            2010--14   Uganda, Kenya, Malawi, Zimbabwe, Zambia                  426                  24                                           1000                                             46 (10.7)              41 (89.1)                                 8 (2.1)^c^                         8 (19.5)^c^                     M46I (8), I54V (7), L76V (3), V82AF (6)

   Boyd \[[@CIT0014]\]                    RCT            2010--14   Nigeria, South Africa                                    100                  12                                           500                                              8 (8.0)                8 (100)                                   0 (0)                              0 (0)                           ...

   Ciaffi \[[@CIT0015]\]^d^               RCT            2010--13   Cameroon, Burkina Faso, Senegal                          451                  12                                           1000 × 2                                         29 (6.4)               5 (17.2)                                  0 (0)                              0 (0)                           ...

   Boender \[[@CIT0025]\]                 POC            2007--11   Kenya, Nigeria, South Africa, Uganda, Zambia, Zimbabwe   205                  12                                           1000                                             21 (10.2)              17 (81.0)                                 2 (1.2)                            2 (11.8)                        M46I (2), I54V (2), L76V(1), V82A (2), L90M (1)

                                                                                                                             177                  24                                           1000                                             26 (14.7)              21 (80.8)                                 6 (4.2)                            6 (28.6)                        M46I (5), I54V (4), L76V(2), V82A (4), I84V (1)

                                                                                                                             90                   36                                           1000                                             8 (8.9)                3 (37.5)                                  2 (5.9)                            2 (66.7)                        M46I (2), I50V (1), I54V (1), V82A (2)

   Johnston \[[@CIT0030]\]                POC            2003--8    South Africa                                             417                  12                                           400                                              112 (26.8)             15 (13.4)                                 0 (0)                              0 (0)                           ...

  Cross-sectional observational studies                                                                                                                                                                                                                                                                                                                                             

   Schramm \[[@CIT0039]\]                 CS             2014--15   Kenya                                                    355                  27 (23--36)                                  500                                              65 (18.3)              65 (100)                                  16 (4.5)                           16 (24.6)                       NA

   Inazule \[[@CIT0038]\]                 CS             2010--15   Kenya                                                    NS                   37 (23--55)                                  1000                                             126 (...)              123 (97.6)                                39 (...)                           39 (31.7)                       M46I/L (30), I54V (27), V82ATFS (25)

   Court \[[@CIT0032]\]                   CS             2009--13   South Africa                                             NS                   20 (13--34)                                  1000                                             164 (...)              134 (81.7)                                28 (...)                           28 (20.9)                       M46I (22), I47VA (2), I50V (1), I54VTALM (24), L76V (19), V82A (22), I84V (2), L90M (1)

   Maiga \[[@CIT0034]\]                   CS             2012       Mali                                                     913                  24 (6--48)                                   500                                              106 (11.6)             93 (87.7)                                 23 (2.9)                           23 (24.7)                       M46I (15), I47V/A (6), I54V (12), L76V(11), V82A (8), I84V (10), L90M (3)

   Ndahimana \[[@CIT0037]\]               CS             2012       Rwanda                                                   74                   31 (18--46)                                  1000                                             35 (47.3)              30 (85.7)                                 5 (7.9)                            5 (16.7)                        L33F (2), M46I (4), I54V (5), L76V (2), V82A (4), I84V (2),

   Levison \[[@CIT0033]\]                 CS             2009       South Africa                                             322                  17 (18)^e^                                   1000 × 2                                         43 (13.3)              33 (76.7)                                 0 (0)                              0 (0)                           ...

   Reynolds \[[@CIT0035]\]                CS             2004--9    Uganda                                                   65                   6 (6--14)                                    2000                                             8 (12.3)               6 (75.0)                                  0 (0)                              0 (0)                           ...

   Wallis \[[@CIT0036]\]                  CS             2008       South Africa                                             NS                   16 (7--18)                                   5000 × 2                                         75 (...)               75 (100)                                  5 (...)                            5 (6.7)                         L33F (2), M46I (4), I54SV (2), L76V (2), V82A (1), I84V (2), L90M (1),
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ART, antiretroviral therapy; CS, cohort study; IQR, interquartile range; NA, genotype not available; NS, not specified; POC, prospective observational cohort; RCT, randomized controlled trial.

^a^As proportion of total at-risk population; adjusted for proportion who underwent sequencing. Major protease resistance mutations as defined by the Stanford HIV drug resistance database \[[@CIT0009]\].

^b^As proportion of failure population; adjusted for proportion who underwent sequencing.

^c^Resistance refers to intermediate or high-level resistance to lopinavir only.

^d^All patients received lopinavir/ritonavir apart from participants in the Ciaffi et al study \[[@CIT0015]\]; 33% were randomized to darunavir/ritonavir, and the remainder received lopinavir/ritonavir.

^e^Standard deviation.

![Proportion of participants with major protease mutations according to duration of second-line antiretroviral therapy at virological failure. Areas of circles are proportional to size of cohort failing second-line treatment. Solid line and dashed line are quadratic line of best fit and 95% confidence interval, respectively. Major protease resistance mutations according to the Stanford HIV resistance database version 8.2 \[[@CIT0009]\]. Abbreviations: ART, antiretroviral therapy; PI, protease inhibitor.](cix110806){#F6}

DISCUSSION {#s21}
==========

By 2030, the number of patients requiring second-line ART in sub-Saharan Africa is estimated to exceed 4 million \[[@CIT0008]\]. Our pooled ITT estimates for virological suppression after 48 and 96 weeks of second-line ART were 69.3% and 61.5%, respectively, demonstrating reasonable efficacy of PI-based therapy with continued NRTI use in these treatment-experienced populations. Employing similar analytical methodologies, studies from India, China, and Cambodia reported virological suppression rates ranging from 70% to 85.7% over 48--96 weeks of second-line ART \[[@CIT0040]\]. RCTs using LPV/r in high-income settings reported comparable virological suppression rates among treatment-experienced patients \[[@CIT0043]\]. Rates of virological suppression with first-line ART in low- and middle-income countries were similar: 67.3% and 64.6% at weeks 48 and week 96, respectively \[[@CIT0044]\]. Thus, first- and second-line ART regimens show overall comparable efficacy in sub-Saharan Africa, despite the widely held assumption that suboptimal adherence may drive first-line failure and continue to reduce responses after patients start second-line ART. Importantly, these rates fall considerably short of the 90% UNAIDS target for virological suppression. Use of a high-genetic-barrier regimen in first-line ART (eg, with dolutegravir) may be required to meet these targets \[[@CIT0045]\]. Although options for first-line ART are expanding, evidence is presently limited for alternative second-line options \[[@CIT0004]\].

One-third of participants did not achieve virological suppression. An important reason in the ITT analysis, and a source of significant heterogeneity between studies, was the proportion of missing VL data (excluding death or loss to follow-up), which varied from 0 to 30%, despite accepting a 24-week window. This finding implies substantial challenges in implementation of VL monitoring. Consistent with this observation, virological outcomes were significantly better and loss to follow-up was lower among RCT participants compared to those from observational studies, a finding that persisted after exclusion of missing VL data. In the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) trial, therapy was delivered in a manner designed to replicate typical program settings with broadly generalizable entry criteria, predominantly nurse-led care and without real-time VL monitoring \[[@CIT0018]\]. Outcomes were comparable to other trials with more restrictive entry criteria that used real-time VL monitoring. Enhanced attention to patient retention, improving staffing, and provision of a constant drug supply are important for ensuring improved treatment outcomes and are likely to account for the observed differences between RCTs and observational studies.

Emergence of drug resistance is common after failure of first-line ART and is typically characterized by mutations affecting both NNRTIs and NRTIs \[[@CIT0046]\]. Interestingly, detection of NRTI resistance and, specifically, thymidine analogue mutations (TAMs) prior to starting second-line ART predicted significantly higher odds of virological suppression \[[@CIT0005], [@CIT0014], [@CIT0020], [@CIT0021], [@CIT0023], [@CIT0030]\]. An explanation is that patients who develop resistance at failure of first-line ART may have overall higher levels of adherence (and therefore greater drug selective pressure) than subjects who experience failure in the absence of resistance \[[@CIT0005]\]. Importantly, the NRTIs commonly included in second-line regimens, such as zidovudine or TDF + 3TC, retain significant residual activity in the presence of TAMs and this is enhanced by continuation of 3TC \[[@CIT0052], [@CIT0053]\]. Data from the SECOND-LINE and EARNEST studies demonstrate that apparent paradoxical benefit of NRTI resistance persists at 96--144 weeks \[[@CIT0005], [@CIT0006]\].

Current reports of HIV epidemic control do not differentiate between first- and second-line ART provision, and rates of second-line failure are not included among metrics of epidemic control or ART program performance \[[@CIT0054]\]. Yet, between 2% and 26% of recipients of second-line ART experienced virological failure by 48 weeks. The optimal public health management of second-line failure has not been adequately defined. In South Africa, 64% of patients experiencing viremia \>400 copies/mL (median, 3.5 log~10~ copies/mL) while on second-line ART regained virological suppression 2--4 months after targeted adherence counseling \[[@CIT0055]\]. This rate of resuppression is consistent with our finding that major protease resistance mutations were uncommon at virological failure, particularly in the first 18 months of second-line ART. Emphasis on adherence is therefore necessary for second-line recipients. This should be differentiated from first-line failure where rapid emergence of NNRTI resistance is likely to limit the impact of adherence support. Effective adherence interventions may include weekly SMS (ie, text messaging) reminders and targeted counseling \[[@CIT0056]\]. In cohort studies from Cambodia \[[@CIT0057]\], India \[[@CIT0040]\], and Vietnam \[[@CIT0058]\], higher rates (42%--68%) of major protease mutations were observed at failure of second-line ART. This higher rate may reflect differences in adherence, duration of failing regimens, or an effect of viral subtypes. In our analysis, rates of PI resistance were strongly associated with increasing duration of second-line ART, suggesting that duration of PI failure is an important determinant of the need for third-line ART. Optimizing the frequency of VL monitoring and the definition of virological failure for second-line ART and defining appropriate regimens for third-line ART represent clear research priorities.

There are a number of limitations in our analysis. First, there was substantial variation in both the duration of first-line ART at the time of switching to second-line ART and the rate of switching to second-line ART among each cohort, which was only reported in 8 studies. The lack of consistency may represent a source of reporting bias. The variation in rate of switching we observed across studies (range, 6--47 per 1000 person years) is consistent with other low- and middle-income settings \[[@CIT0007]\]. In programs with routine VL monitoring, rates of switching are 3 times higher, suggesting potentially different outcomes in programs without monitoring \[[@CIT0007]\]. Second, our analysis used aggregate rather than individual patient data and, therefore, it was not possible to analyze the contribution of individual risk factors to outcomes. Third, most studies applied a VL \<400 copies/mL to denote suppression. Data from South Africa demonstrate a continuum of risk of virological failure even with the lowest level of viremia (50--199 copies/mL), indicating that low-level viremia should trigger adherence interventions and repeat VL measurement \[[@CIT0059]\]. Fourth, zidovudine and stavudine, previously common components of ART regimens in sub-Saharan Africa, have now been replaced by TDF, and impact on NRTI resistance profiles and second-line ART efficacy is to be demonstrated \[[@CIT0060]\].

In summary, reported rates of virological suppression among patients receiving second-line PI-based ART in sub-Saharan Africa are similar to those observed with first-line ART and comparable to the outcomes of similar regimens in Asian and Western settings. There is a significant gap in achieving the third part of the WHO 90-90-90 strategy for epidemic control. Reporting of second-line ART provision and rates of virological suppression among recipients is crucial to understanding of epidemic control and should be strongly encouraged. Given that more than one-third of patients did not achieve virological suppression, defining the optimal definition and management of second-line ART failure, both with and without PI resistance, in this setting is an urgent research priority.
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